Department of Biology, Indiana University Purdue University Indianapolis, Indianapolis, IN, USA.
Division of Pediatric Neurosurgery, Ann and Robert H. Lurie Children's Hospital, Chicago, IL, USA.
Eur J Med Res. 2022 Sep 1;27(1):168. doi: 10.1186/s40001-022-00798-6.
Hydrocephalus is a serious condition that affects patients of all ages, resulting from a multitude of causes. While the etiologies of hydrocephalus are numerous, many of the acute and chronic symptoms of the condition are shared. These symptoms include disorientation and pain (headaches), cognitive and developmental changes, vision and sleep disturbances, and gait abnormalities. This collective group of symptoms combined with the effectiveness of CSF diversion as a surgical intervention for many types of the condition suggest that the various etiologies may share common cellular and molecular dysfunctions. The incidence rate of pediatric hydrocephalus is approximately 0.1-0.6% of live births, making it as common as Down syndrome in infants. Diagnosis and treatment of various forms of adult hydrocephalus remain understudied and underreported. Surgical interventions to treat hydrocephalus, though lifesaving, have a high incidence of failure. Previously tested pharmacotherapies for the treatment of hydrocephalus have resulted in net zero or negative outcomes for patients potentially due to the lack of understanding of the cellular and molecular mechanisms that contribute to the development of hydrocephalus. Very few well-validated drug targets have been proposed for therapy; most of these have been within the last 5 years. Within the last 50 years, there have been only incremental improvements in surgical treatments for hydrocephalus, and there has been little progress made towards prevention or cure. This demonstrates the need to develop nonsurgical interventions for the treatment of hydrocephalus regardless of etiology. The development of new treatment paradigms relies heavily on investment in researching the common molecular mechanisms that contribute to all of the forms of hydrocephalus, and requires the concerted support of patient advocacy organizations, government- and private-funded research, biotechnology and pharmaceutical companies, the medical device industry, and the vast network of healthcare professionals.
脑积水是一种影响各年龄段患者的严重疾病,其病因众多。虽然脑积水的病因很多,但许多急性和慢性症状是共有的。这些症状包括定向障碍和疼痛(头痛)、认知和发育变化、视力和睡眠障碍以及步态异常。这些共同的症状再加上 CSF 引流作为许多类型脑积水的手术干预的有效性,表明各种病因可能存在共同的细胞和分子功能障碍。小儿脑积水的发病率约为活产婴儿的 0.1%-0.6%,与婴儿唐氏综合征的发病率相当。各种类型成人脑积水的诊断和治疗仍研究不足且报道较少。尽管治疗脑积水的手术干预可以挽救生命,但失败的发生率很高。以前针对脑积水治疗的药物疗法的测试结果为零或负面,这可能是由于缺乏对导致脑积水发展的细胞和分子机制的理解。很少有经过充分验证的药物靶点被提出用于治疗;其中大多数是在过去 5 年提出的。在过去的 50 年里,脑积水的手术治疗只有微小的改进,在预防或治愈方面几乎没有取得进展。这表明,无论病因如何,都需要开发非手术干预措施来治疗脑积水。新治疗方案的发展在很大程度上依赖于对导致所有类型脑积水的共同分子机制的研究投资,这需要患者权益组织、政府和私人资助的研究、生物技术和制药公司、医疗器械行业以及庞大的医疗保健专业人员网络的协同支持。